Please assess the completion status of the following clinical trial:

Trial Title: Phase I Trial of an Investigational Small Pox Medication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 to 50 years~2. Available for clinical follow-up duration of study.~3. Able/willing to give written consent.~4. Good general health; no clinically significant medical history.~5. Refrain from taking any medications from screening through 72 hours after last dose.~6. Adequate venous access.~7. PE and lab results without clinically significant findings within 28 days prior to receipt of drug.~8. Meet Lab Criteria within 28 days prior to receipt of drug.~9. Negative pregnancy test~10. Non smokers~11. No alcohol or caffeine~12. Participant or partner has undergone surgical sterilization, or the participant agrees either to be abstinent or use two non-hormonal methods of contraception for duration of the study~Exclusion Criteria:~1. Marked baseline prolongation of QT/corrected QT interval (QTc) interval (~2. History of additional risk factors for Torsade de Pointes~3. Clinically significant abnormal ECG~4. Personal history of cardiac disease, symptomatic or asymptomatic arrhythmias, syncopal episodes, or prolongation of the PR interval~5. Family history of Sudden Cardiac Death not clearly due to acute myocardial infarction.~6. History of any clinically significant conditions including:~   * Asthma~  * Diabetes mellitus~  * History of thyroidectomy or thyroid disease~  * Serious angioedema episodes~  * Head trauma resulting in a diagnosis of TBI other than concussion~  * Seizure or history of seizure~  * Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with intramuscular injections or blood draws~  * Malignancy~7. Family history of idiopathic seizures~8. History or presence of neutropenia or other blood dyscrasia~9. Known Hepatitis B or Hepatitis C infection~10. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome illness.~11. Current or recent history of a clinically significant bacterial, fungal, or mycobacterial infection.~12. Known clinically significant chronic viral infection (or current clinically significant viral infection~13. History of frequent or severe headaches or migraines~14. Known chronic bacterial, mycobacterial, fungal, parasitic, or protozoal infection~15. Woman who is pregnant or is breast-feeding or planning to become pregnant~16. On any concomitant medications~17. History of drug allergy that, in the opinion of the PI, contraindicates participation in the trial.~18. Inability to swallow medication~19. Body Mass Index above 35 or below 18,~20. Current drug abuse or alcohol abuse.~21. Inability to refrain from physical exercise for a period of 24 hr before and after a PK day or refrain from consuming xanthines, grapefruit or grapefruit juice~22. Clinically significant lactose intolerance~23. Received experimental drug within 30 days~24. Vaccination within 30 days~25. Total of more than 350 milliliters (mL) of blood drawn in 2 months~26. Treatment with any immunosuppressant or immunomodulatory medication in 3 months~27. Any condition occupational reason or other responsibility that, in the judgment of the PI, would jeopardize the safety or rights of a subject participating in the trial or would render the subject unable to comply with the protocol~28. History or diagnosis that would affect absorption of study medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Group ST-246 Form I (followed by Form V) (Type: ACTIVE_COMPARATOR): Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat.
- Group ST-246 Form V (followed by Form I) (Type: ACTIVE_COMPARATOR): Each of six subjects receive a single oral 400 mg dose (2×200 mg) of ST-246 Form V (hemihydrate) in the first intervention period, followed 10 days later (3 days post-treatment monitoring and 7 days wash-out period) in the second intervention period by a single oral 400 mg dose (2×200 mg) of ST-246 Form I (monohydrate). Both forms of drug are orally administered within 30 minutes after a standard light meal consisting of 400-450 calories and approximately 25% fat.

Based on this trial design, predict the completion outcome and termination type (if applicable).